This week, Abeona Therapeutics is proudly attending the American Academy of Dermatology (AAD) Annual Meeting and the 36th Annual Society for Pediatric Dermatology Pre-AAD Meeting in San Diego. We are excited to be here and committed to supporting advancements in treatments for people living with severe dystrophic epidermolysis bullosa (DEB). Stay up to date on the latest advances in severe DEB by visiting bit.ly/3IpLygx #PreAAD2024 #AAD2024 #SevereDEB #RDEB #AbeonaTherapeutics #WeFightEB
Abeona Therapeutics’ Post
More Relevant Posts
-
I am privileged to share our new article published in the American Journal of Clinical Dermatology, which focuses on the use of topical calcineurin inhibitors on atopic dermatitis patients among the Taiwanese population. Please feel free to discuss and share your comments with me! https://lnkd.in/gYnFpfMh #atopicdermatitis #cohortstudy #topicalcalcineurininhibitors #NationalHealthinsuranceResearchDatabase
-
-
📚 Would you like to access the latest dermatology news? 📚 Discover our medical reviews on Ask NAOS Pro 👇 https://lnkd.in/dKjMgYZZ The medical reviews offer privileged access to scientific information from international events dedicated to dermatology 🎉 They are a summary of: • Our symposia held during the latest WCD2027, IMCAS, and European Academy of Dermatology and Venereology • Our e-symposia organized in cooperation with the University of Brescia, dedicated to Onco-Dermatology • Meetings of the European Society for Photodermatology, giving an overview of the main topics presented during the previous World Photodermatology Days. #Atopy #Hyperpigmentation #Oncology #Aging #Photoprotection #Photodermatology
-
-
New Publication in Dermatology and Therapy: The analysis of an IL-13 inhibitor across EASI body regions and clinical signs of Atopic Dermatitis, results from ADvocate 1 & ADvocate 2 trials. View the full publication here: https://e.lilly/4ayAaKR
-
Exploring the World of Dermatology! In Ep. 59 of Derms and Conditions, Dr. Bunick from Yale University and our host Dr. Del Rosso dive deep into the world of monoclonal antibodies and JAK inhibitors. Discover the latest insights on treating skin conditions and the fascinating science behind it! https://lnkd.in/eXkikE6A
-
-
Access to biologic therapies is a critical issue in dermatology. We're thrilled to share Jason Zemcik's article from the latest edition of Access Dermatology Magazine, discussing key trends and solutions. Thank you for your contributions, Jason! Read more in our latest issue. ⬇️ #PatientAccess #Dermatology #Biologics #BCOD
In the latest edition of Access Dermatology Magazine I discuss trends impacting patient access to biologic therapies, and ways providers’ staff can help overcome these challenges. Thank you Craig Schuette and Biologic Coordinators of Dermatology (BCoD) for this opportunity! Link in comments. Policy Reporter Mercalis
-
-
Our 2023 results are out! Last year, we reached more than 95 million people with our dermatology and thrombosis medicines. At the same time, our transformation is on track with a clear strategy to make a fundamental difference for those who need us the most in medical dermatology. Learn more about our results and ambitions in our Annual Report. And read the press release at https://lnkd.in/etbTq-Y #LEOPharma #DermatologyBeyondTheSkin
-
-
Excellent 9th Update and Advances in Pediatric Dermatology, directed by Antonio Torrelo. Interesting presentation of Atopic dermatitis in children-what is past and what is present. Importance of avoiding undertreatment and identification of clinical phenotypes! #atopicdermatitis #topicalcorticosteroids #pimecrolimus
-
Lots of exciting developments in #psoriasis #psoriaticarthritis #lupus to follow. I guess that's why #venturecapital investing $250M+ here. #clinicaltrials #arthritis #medicine #heathcare
Today we presented positive data from a Phase 2 clinical trial of ESK-001, a highly selective allosteric TYK2 inhibitor, for the treatment of plaque #psoriasis at the American Academy of Dermatology Annual Meeting. Learn more: https://lnkd.in/e9pKPCBM #AAD2024
-
-
Account Development Representative RWE ppd Clinical Research Services Thermo Fisher Scientific
Want to learn more about our AtopicDermatitis registry. Let’s schedule a meeting and discuss how we can support your dermatology development initiatives. #rwe #rwd #registry #atopicdermatitis
Now available online American Academy of Dermatology #JAAD: our co-authored research paper. It describes the demographic, clinical, and treatment characteristics among CorEvitas #AtopicDermatitis (AD) Registry patients in the first 2.5 years after inception and stratified by current systemic therapy use. https://hubs.la/Q02rbhvB0 #RWE #RWD #diseaseregistry
-
-
Arash Mostaghimi, MD, MPA, MPH and colleagues provide an updated systematic review and meta-analysis of medical comorbidities associated with alopecia areata and identified 57 comorbidities with positive odds ratios and 6 comorbidities with negative odds ratios. In the American Journal of Clinical Dermatology - see link below. #alopeciaareata #comorbidities #metaanalysis
